Skip to content
Governance Register

← US public companies

Aprea Therapeutics, Inc.

SEC CIK 1781983 · APRE · last insider filing 2026-06-17

Directors (from insider filings)

NameCapacity as filedFilings
Henneman John B III Director filed 2019–2026
Bizzari Jean-Pierre Director filed 2023–2026
Peters Richard Director filed 2020–2026
Grissinger Michael Director filed 2022–2026
Seizinger Bernd R. Director filed 2019–2026
Gruia Gabriela Director filed 2023–2026
Duey Marc Director filed 2022–2026
Pamukcu Rifat Director filed 2022–2026
Gilad Oren Director · President/CEO filed 2022–2026
Schade Christian S Director · President & CEO filed 2019–2022
Coiante Scott M Director · SVP, Chief Financial Officer filed 2019–2022
Korbel Gregory Alan Director · VP of Business Dev't filed 2019–2022
Attar Eyal C. Director · SVP, Chief Medical Officer filed 2019–2022
Kelly Michael Aaron Director filed 2020–2021
Namouni Fouad Director filed 2020–2021
Rocklage Scott M Director filed 2019–2020
Christenson Johan Director filed 2019–2020
Hepple Jonathan Director filed 2019–2020
Magni Guido Director filed 2019–2019

Officers (from insider filings)

NameTitle as filedFilings
Hamill John P. SrVP/CFO/Prin. Fin&Acctg. Off filed 2023–2026
Mirza Nadeem Q. Chief Medical Officer filed 2024–2024
Abrahmsen Lars B. SVP, Chief Scientific Officer filed 2019–2022
Wessels Gregory S. SVP, Chief Commercial Officer filed 2020–2021

About this record

From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.

Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.